Memorial Sloan Kettering Cancer Center - Q2 2021 holdings

$153 Million is the total value of Memorial Sloan Kettering Cancer Center's 4 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .

 Value Shares↓ Weighting
RPRX  ROYALTY PHARMA PLC$109,880,000
-6.0%
2,680,6440.0%71.84%
-0.3%
GDX  VANECK VECTORS ETF TRgold miners etf$25,094,000
+4.6%
738,5000.0%16.41%
+10.9%
ORIC  ORIC PHARMACEUTICALS INC$10,654,000
-27.8%
602,2720.0%6.96%
-23.4%
YMAB  Y-MABS THERAPEUTICS INC$7,332,000
+11.8%
216,9160.0%4.79%
+18.6%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
VANECK VECTORS ETF TR12Q3 202380.9%
ORIC PHARMACEUTICALS INC12Q3 202314.8%
Y-MABS THERAPEUTICS INC12Q3 20239.6%
CARIBOU BIOSCIENCES INC8Q2 202319.5%
ILLUMINA INC8Q2 20234.4%
ROYALTY PHARMA PLC6Q1 202275.6%

View Memorial Sloan Kettering Cancer Center's complete holdings history.

Latest significant ownerships (13-D/G)
Memorial Sloan Kettering Cancer Center Q2 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Y-mAbs Therapeutics, Inc.February 14, 2020257,5170.6%
Actinium Pharmaceuticals, Inc.February 13, 20181,230,9541.5%
Cactus Ventures, Inc.January 18, 20135,702,38734.7%

View Memorial Sloan Kettering Cancer Center's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-10
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-15
13F-HR2021-08-16

View Memorial Sloan Kettering Cancer Center's complete filings history.

Compare quarters

Export Memorial Sloan Kettering Cancer Center's holdings